quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:31:10·32d
SECFiling
Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

ABUS· Arbutus Biopharma Corporation
Health Care
Original source

Companies

  • ABUS
    Arbutus Biopharma Corporation
    Health Care

Recent analyst ratings

  • Mar 4UpdateChardan Capital$6.00
  • Feb 2UpdateJefferies$5.00
  • Nov 8UpdateJMP Securities$9.00

Related

  • SEC9d
    Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR9d
    Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
  • SEC9d
    SEC Form DEFA14A filed by Arbutus Biopharma Corporation
  • SEC9d
    SEC Form DEF 14A filed by Arbutus Biopharma Corporation
  • SEC32d
    SEC Form 10-K filed by Arbutus Biopharma Corporation
  • PR32d
    Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
  • SEC51d
    Arbutus Biopharma Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
  • PR51d
    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022